LEVODOPA/CARBIDOPA/ENTACAPONE EG 200 mg/50 mg/200 mg, film-coated tablet 100 tablets
Active ingredients: (S)-(−)-carbidopa, CARBIDOPA MONOHYDRATÉE, Entacapone, LÉVODOPA
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet100 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- LEVODOPA/CARBIDOPA/ENTACAPONE EG 200 mg/50 mg/200 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- flacon(s) polyéthylène haute densité (PEHD) de 100 comprimé(s)
- Marketing authorisation holder
- EG LABO - LABORATOIRES EUROGENERICS
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 31 Oct 2025
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
68080241CIP73000353CIP133400930003534Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LÉVODOPAcomprimé | 200 mg · un comprimé | SA |
| CARBIDOPA ANHYDREcomprimé | 50 mg · un comprimé | FT |
| CARBIDOPA MONOHYDRATÉEcomprimé | — | SA |
| ENTACAPONEcomprimé | 200 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.